Compare Fubotv Inc (FUBO) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs TransMedics Group Inc — how do they compare? Fubotv Inc trades at $8.84 (market cap $1.02B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 2.7× Fubotv Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fubotv Inc for 35 Days and TransMedics Group Inc for 24 Days on average.
| FUBO | TMDX | |
|---|---|---|
Market Cap | $1.02B | $2.74B |
Volume | 978,631 | 949,331 |
Sector | Media | Health |
52-Week High | $48.96 | $150.42 |
52-Week Low | $8.09 | $61.99 |
Typical Hold Time | 35 Days | 24 Days |
Enterprise Value | $1.19B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.35, up 1.08% on the day, with a bearish technical signal from moving averages and neutral oscillators. The company reported revenue of $1.62 billion in 2024, with a net loss of $172.25 million, though the net income margin improved to -10.62%. Recent news highlights strategic partnerships with the NHL and The Athletic to expand sports content offerings. Analyst consensus is a Buy with a $63.38 price target, but cash flow remains negative, and the stock is heavily shorted.
The outlook for FUBO hinges on its ability to achieve profitability through subscriber growth and cost management. Opportunities include leveraging Disney's operational expertise and new sports distribution deals. Key risks are persistent cash burn, high debt levels, and intense competition in the streaming sector. The stock presents a speculative opportunity with significant upside if turnaround efforts succeed, but investors should be cautious of execution risks and market volatility.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
